Association Between Prediabetes and Risk, Mortality of Hepatocellular Carcinoma: A Meta-Analysis

References

• Zhang CH, Cheng Y, Zhang S, Fan J, Gao Q. Changing epidemiology of hepatocellular carcinoma in Asia. Liver Int. 2022;42(9):2029–2041. doi:10.1111/liv.15251.
   PubMed Web of Science ®Google Scholar
• Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16(10):589–604. doi:10.1038/s41575-019-0186-y.
   PubMed Web of Science ®Google Scholar
• Kulik L, El-Serag HB. Epidemiology and management of hepatocellular carcinoma. Gastroenterology. 2019;156(2):477–91.e1. doi:10.1053/j.gastro.2018.08.065.
   PubMed Web of Science ®Google Scholar
• Frager SZ, Schwartz JM. Hepatocellular carcinoma: epidemiology, screening, and assessment of hepatic reserve. Curr Oncol. 2020;27(Suppl 3):S138–s43. doi:10.3747/co.27.7181.
   PubMed Web of Science ®Google Scholar
• Massarweh NN, El-Serag HB. Epidemiology of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Cancer Control. 2017;24(3):1073274817729245. doi:10.1177/1073274817729245.
   Web of Science ®Google Scholar
• Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–1314. doi:10.1016/S0140-6736(18)30010-2.
   PubMed Web of Science ®Google Scholar
• Wilson ML. Prediabetes: beyond the borderline. Nurs Clin North Am. 2017;52(4):665–677. doi:10.1016/j.cnur.2017.07.011.
   PubMed Web of Science ®Google Scholar
• Rett K, Gottwald-Hostalek U. Understanding prediabetes: definition, prevalence, burden and treatment options for an emerging disease. Curr Med Res Opin. 2019;35(9):1529–1534. doi:10.1080/03007995.2019.1601455.
   PubMed Web of Science ®Google Scholar
• Huang Y, Cai X, Mai W, Li M, Hu Y. Association between prediabetes and risk of cardiovascular disease and all cause mortality: systematic review and meta-analysis. BMJ. 2016;355:i5953. doi:10.1136/bmj.i5953.
   PubMed Web of Science ®Google Scholar
• Tabák AG, Herder C, Rathmann W, Brunner EJ, Kivimäki M. Prediabetes: a high-risk state for diabetes development. Lancet. 2012;379(9833):2279–2290. doi:10.1016/S0140-6736(12)60283-9.
   PubMed Web of Science ®Google Scholar
• Wang L, Gao P, Zhang M, Huang Z, Zhang D, Deng Q, Li Y, Zhao Z, Qin X, Jin D and Zhou M. Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013. JAMA. 2017;317(24):2515–2523. doi:10.1001/jama.2017.7596.
   PubMed Web of Science ®Google Scholar
• Tanaka K, Tsuji I, Tamakoshi A, Matsuo K, Wakai K, Nagata C, Mizoue T, Inoue M, Tsugane S, Sasazuki, S and Sasazuki, S. Diabetes mellitus and liver cancer risk: an evaluation based on a systematic review of epidemiologic evidence among the Japanese population. Jpn J Clin Oncol. 2014;44(10):986–999. doi:10.1093/jjco/hyu108.
   PubMed Web of Science ®Google Scholar
• Xu K, Wang L, Mai J, He L. Efficacy of constraint-induced movement therapy and electrical stimulation on hand function of children with hemiplegic cerebral palsy: a controlled clinical trial. Disabil Rehabil. 2012;34(4):337–346. doi:10.3109/09638288.2011.607213.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339(jul21 1):b2535. Clinical research ed doi:10.1136/bmj.b2535.
   PubMed Web of Science ®Google Scholar
• Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM. Fasting serum glucose level and cancer risk in Korean men and women. JAMA. 2005;293(2):194–202. doi:10.1001/jama.293.2.194.
   PubMed Web of Science ®Google Scholar
• Gwack J, Hwang SS, Ko KP, Jun JK, Park SK, Chang SH, Shin H. R and Yoo K Y. Fasting serum glucose and subsequent liver cancer risk in a Korean prospective cohort. J Preventive Med Public Health = Yebang Uihakhoe Chi. 2007;40(1):23–28. doi:10.3961/jpmph.2007.40.1.23.
   PubMedGoogle Scholar
• Chao LT, Wu CF, Sung FY, Lin CL, Liu CJ, Huang CJ, et al. Insulin, glucose and hepatocellular carcinoma risk in male hepatitis B carriers: results from 17-year follow-up of a population-based cohort. Carcinogenesis. 2011;32(6):876–881. doi:10.1093/carcin/bgr058.
   PubMed Web of Science ®Google Scholar
• Gupta SP, Mittal A, Sathian B, Jha DK. Elevated serum insulin is an independent risk factor for hepatocellular carcinoma: a case control study from Nepal. Asian Pac J Cancer Prev. 2013;14(12):7331–7333. doi:10.7314/APJCP.2013.14.12.7331.
   PubMedGoogle Scholar
• Roujun C, Yanhua Y, Bixun L. High prevalence of diabetes mellitus and impaired glucose tolerance in liver cancer patients: A hospital based study of 4610 patients with benign tumors or specific cancers. F1000res. 2016;5:1397. doi:10.12688/f1000research.8457.1.
   PubMedGoogle Scholar
• Feng X, Wang G, Li N, Lyu Z, Chen S, Wei L, Chen, Y, Xie, S, Yang, W, Yin, J and Cui, H. The association between fasting blood glucose and the risk of primary liver cancer in Chinese males: a population-based prospective study. Br J Cancer. 2017;117(9):1405–1411. doi:10.1038/bjc.2017.296.
   PubMed Web of Science ®Google Scholar
• Chen CL, Kuo MJ, Yen MF, Yang WS, Kao JH, Chen PJ, et al. Gender difference in the association between metabolic factors and hepatocellular carcinoma. JNCI Cancer Spectrum. 2020;4(5). 10.1093/jncics/pkaa036.
   Web of Science ®Google Scholar
• Batty GD, Shipley MJ, Marmot M, Smith GD. Diabetes status and post-load plasma glucose concentration in relation to site-specific cancer mortality: findings from the original Whitehall study. Cancer Causes & Control: CCC. 2004;15(9):873–881. doi:10.1007/s10552-004-1050-z.
   PubMed Web of Science ®Google Scholar
• Khan MM, Saito S, Takagi S, Ohnishi H, Izumi H, Sakauchi F, et al. Relationship between hepatocellular carcinoma and impaired glucose tolerance among Japanese. Hepatogastroenterology. 2006;53(71):742–746.
   PubMedGoogle Scholar
• Zhou XH, Qiao Q, Zethelius B, Pyörälä K, Söderberg S, Pajak A, et al. Diabetes, prediabetes and cancer mortality. Diabetologia. 2010;53(9):1867–1876. doi:10.1007/s00125-010-1796-7.
   PubMed Web of Science ®Google Scholar
• Huang Y, Cai X, Qiu M, Chen P, Tang H, Hu Y, et al. Prediabetes and the risk of cancer: a meta-analysis. Diabetologia. 2014;57(11):2261–2269. doi:10.1007/s00125-014-3361-2.
   PubMed Web of Science ®Google Scholar
• Xu WG, Qian YF, Wu J. The effect of prediabetes on hepatocellular carcinoma risk: a systematic review and meta-analysis. Minerva Med. 2017;108(2):185–190. doi:10.23736/S0026-4806.16.04601-2.
   PubMed Web of Science ®Google Scholar
• Plaz Torres MC, Jaffe A, Perry R, Marabotto E, Strazzabosco M, Giannini EG. Diabetes medications and risk of HCC. Hepatology. 2022;76(6):1880–1897. doi:10.1002/hep.32439.
   PubMed Web of Science ®Google Scholar
• Janssen J. Hyperinsulinemia and its pivotal role in aging, obesity, type 2 diabetes, cardiovascular disease and cancer. Int J Mol Sci. 2021;22(15):7797. doi:10.3390/ijms22157797.
   PubMed Web of Science ®Google Scholar
• Luc K, Schramm-Luc A, Guzik TJ, Mikolajczyk TP. Oxidative stress and inflammatory markers in prediabetes and diabetes. J Physiol Pharmacol. 2019;70(6). 10.26402/jpp.2019.6.01.
   PubMed Web of Science ®Google Scholar
• Shen Z, Zhou H, Li A, Wu T, Ji X, Guo L, et al. Metformin inhibits hepatocellular carcinoma development by inducing apoptosis and pyroptosis through regulating FOXO3. Aging (Albany NY). 2021;13(18):22120–22133. doi:10.18632/aging.203464.
   PubMedGoogle Scholar
• Tseng CH. Metformin and risk of hepatocellular carcinoma in patients with type 2 diabetes. Liver Int. 2018;38(11):2018–2027. doi:10.1111/liv.13872.
   PubMed Web of Science ®Google Scholar